Vela Pharmaceuticals Inc. - R&D Services

Vela Pharmaceuticals Inc.
Vela Pharmaceuticals Inc. (VelaSM) ?rediscovers? and develops medicines to treat diseases related to neurotransmitters and the nervous system, including the brain-gut axis. Vela currently has several later-stage assets in development for such indications as Irritable Bowel Syndrome and Major Depressive Disorder.
By starting with molecules that have already been tested in humans, Vela minimizes the risks of traditional drug discovery and development. Taking full or partial ownership of such assets, the Vela team puts it all into safe, efficient and fast development. The Company?s ability to design and run clinical trials in complex indications is second to none.
Vela is led by experienced CRO and pharmaceutical executives. Vela?s President and CEO is Kevin L. Keim, Ph.D., M.Sc., the former president of Quintiles? CNS Therapeutics group. He has recruited top performers from such organizations as Quintiles, McKinsey & Company, Pharmacia, Wyeth-Ayerst, Roche, Cephalon, and JP Morgan.
Based in Ewing, NJ, Vela was incorporated in 1998. The company is backed by venture funding from New Enterprise Associates, JP Morgan Partners, Venrock Associates, and others.
Vela Pharmaceuticals Inc.
3131 Princeton Pike
Building 4, Suite 216
Lawrenceville, NJ 08648
(609) 895-8352 (phone)
(609) 895-8353 (fax)